Benzinga··Globe NewswireGyre Therapeutics Completes $300M Cullgen Acquisition, Eyes Fibrosis Market
Gyre Therapeutics completes all-stock acquisition of Cullgen for ~$300M, creating integrated biopharmaceutical company with U.S.-China operations and commercial-stage fibrosis drug.
GYREacquisitionclinical development